COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #34 of 230
5/11 Late treatment study
Shabrawishi et al., medRxix, doi:10.1101/2020.05.08.20095679 (Preprint)
Negative nasopharyngeal SARS-CoV-2 PCR conversion in response to different therapeutic interventions
Source   PDF   Share   Tweet
Retrospective 93 hospitalized patients in Saudi Arabia showing a non-statistically significant 15% reduction in PCR positive results at day 5, RR 0.85, p = 0.65. The treatment group had significantly more severe illness and significantly more male patients.

Shabrawishi et al., 5/11/2020, retrospective, Saudi Arabia, Middle East, preprint, mean age 43.9, 5 authors.
risk of no virological cure at day 5, 14.7% lower, RR 0.85, p = 0.66, treatment 12 of 45 (26.7%), control 15 of 48 (31.2%).
Details of all 230 studies    Meta analysis
Please submit corrections, updates, or comments.